title: Anti-cancer activity of DHA on gastric cancer--an in vitro and in vivo study.
abstract: Treatment of gastric cancer remains a major challenge, and new anticancer drugs are urgently required. This study investigated whether dihydroartemisinin (DHA), a semi-synthetic derivative of artemisinin, could inhibit the growth of gastric cancer both in vitro and in vivo. A series of in vitro experiments including MTT, colony-forming, wound healing, invasion, cell cycle, cellular senescence, and apoptosis assays were performed to examine the antiproliferative and antimetastatic effects of DHA on three gastric cancer cell lines, SGC-7901, BGC823, and MGC803. The result showed that the proliferation rate and colony-forming abilities of gastric cancer cells were significantly suppressed by DHA together with significant suppression of the expressions of proliferation markers (PCNA, cyclin E, and cyclin D1), and upregulation of p21 and p27. Moreover, DHA induced cellular senescence, G1 phase cell cycle arrest and hindered the migration and invasion of gastric cancer cells corresponding with downregulation of MMP-9 and MMP-2. Furthermore, DHA significantly induced apoptosis through suppressing Bcl-2 as well as activating caspase-9 and PARP. Treatment of gastric cancer cells with DHA increased miR-15b and miR-16 expression, caused a downregulation of Bcl-2, resulting in apoptosis of gastric cancer cells. In vivo, our data showed that DHA significantly inhibited the growth of SGC7901 cell-transplanted tumors. In summary, we have shown that DHA is able to inhibit the growth and metastasis of human gastric cancer. The modulation of miR-15b and miR-16 mediated the apoptosis effects of DHA in gastric cancer cells. Our work suggested that DHA has significant anticancer effects against gastric cancer both in vivo and in vitro, indicating that it is a promising therapy for human gastric cancer.
authors.affiliation: Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, No. 23 Youzheng Street, Harbin, Heilongjiang Province, 150001, China.
authors.forename: Haijun
authors.initials: H
authors.lastname: Sun
authors.forename: Xianzhi
authors.initials: X
authors.lastname: Meng
authors.forename: Jihua
authors.initials: J
authors.lastname: Han
authors.forename: Zhe
authors.initials: Z
authors.lastname: Zhang
authors.forename: Bing
authors.initials: B
authors.lastname: Wang
authors.forename: Xuedong
authors.initials: X
authors.lastname: Bai
authors.forename: Xin
authors.initials: X
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D037621:Artemisinins / Q000494:pharmacology*; D015153:Blotting, Western; D002453:Cell Cycle / Q000187:drug effects; D018797:Cell Cycle Proteins / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005753:Gastric Mucosa / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D035683:MicroRNAs / Q000235:genetics; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013270:Stomach / Q000187:drug effects* / Q000473:pathology; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D037621:Artemisinins; D018797:Cell Cycle Proteins; C505361:MIRN15 microRNA, human; C505362:MIRN16 microRNA, human; D035683:MicroRNAs; D019253:Proto-Oncogene Proteins c-bcl-2; C039060:artenimol; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9
references.citation: Cancer Chemother Pharmacol. 2010 May;66(1):21-9
references.pmid: 19756601
references.citation: Cancer Chemother Pharmacol. 2006 Jan;57(2):213-20
references.pmid: 16075280
references.citation: Chem Soc Rev. 2010 Feb;39(2):435-54
references.pmid: 20111769
references.citation: Methods Find Exp Clin Pharmacol. 2007 Jan-Feb;29(1):33-8
references.pmid: 17344942
references.citation: Clin Cancer Res. 2008 Sep 1;14(17):5519-30
references.pmid: 18765544
references.citation: Cancer Chemother Pharmacol. 2008 Apr;61(4):639-45
references.pmid: 17609948
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: Acta Pharmacol Sin. 2007 Jul;28(7):1045-56
references.pmid: 17588342
references.citation: PLoS One. 2013;8(3):e59827
references.pmid: 23536891
references.citation: J Biomed Sci. 2009 Feb 02;16:16
references.pmid: 19272183
references.citation: Future Oncol. 2010 Apr;6(4):527-37
references.pmid: 20373867
references.citation: Int J Pharm. 2008 Apr 16;354(1-2):28-33
references.pmid: 17942255
references.citation: Biochem Pharmacol. 2012 May 1;83(9):1278-89
references.pmid: 22342732
references.citation: Int J Cancer. 2008 Jul 15;123(2):372-379
references.pmid: 18449891
references.citation: Int J Cancer. 2005 Dec 20;117(6):1039-48
references.pmid: 15986440
references.citation: Int J Cancer. 2010 Jan 1;126(1):2-10
references.pmid: 19634138
references.citation: Anticancer Drugs. 2008 Mar;19(3):247-55
references.pmid: 18510170
references.citation: Cancer Lett. 1995 Nov 27;98(1):83-7
references.pmid: 8529210
references.citation: Am J Vet Res. 2008 Apr;69(4):519-26
references.pmid: 18380584
references.citation: Expert Rev Mol Med. 2010 Sep 08;12:e28
references.pmid: 20822554
references.citation: Head Neck. 2007 Apr;29(4):335-40
references.pmid: 17163469
references.citation: Bioorg Med Chem Lett. 2009 Aug 1;19(15):4385-8
references.pmid: 19501507
references.citation: Life Sci. 2001 Nov 21;70(1):49-56
references.pmid: 11764006
references.citation: Curr Opin Gastroenterol. 2010 Nov;26(6):640-6
references.pmid: 20827183
references.citation: J Cancer Res Clin Oncol. 2006 Feb;132(2):129-35
references.pmid: 16273420
references.citation: Cancer Biol Ther. 2008 Jul;7(7):1017-23
references.pmid: 18414062
references.citation: J Cell Biochem. 2010 Sep 1;111(1):218-28
references.pmid: 20506484
references.citation: Cancer Lett. 2010 Jul 1;293(1):99-108
references.pmid: 20137856
references.citation: Pharmacol Res. 2003 Sep;48(3):231-6
references.pmid: 12860439
references.citation: Int J Cancer. 2010 Dec 1;127(11):2520-9
references.pmid: 20162574